Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small cell lung cancer. Genentech disclosed results from the ATLAS trial Feb. 2
Advertisement

Related Content

Tarceva Advisory Committee To Focus On Treatment Alternatives, Subgroup Concerns
Tarceva Advisory Committee To Focus On Treatment Alternatives, Subgroup Concerns
Roche Ups Negotiating Ante With Hostile Bid For Genentech
OSI: Tarceva Sales Strong, Data Due This Year In Bid For Wider Label
OSI: Tarceva Sales Strong, Data Due This Year In Bid For Wider Label
Amgen’s Colorectal Cancer Program Proceeding Despite Vectibix PACCE Failure

Topics

Advertisement
UsernamePublicRestriction

Register

PS004055

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel